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According to the onset, we can distinguish “early onset sepsis” when microbiological cultures
positive for external pathogens come from newborns during the first 7 days of life (maternal
intrapartum transmission); “late onset sepsis” when microbiological cultures positive for
external pathogens come from newborns after the first 7 days from delivery (postnatal acqui-
sition). In this review we synthesize the incidence, risk factors, clinical manifestations, and
methods of diagnosis and treatment of each type of neonatal infection, in order to better
define such a pathological condition which is of great importance in common clinical practice.
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by-nc-nd/4.0/).1. Introduction
Neonatal sepsis still represents an important cause of
mortality and morbidity among infants, above all in very-
low-birth-weight (VLBW, birth weight < 1500 g) pretermascular Diseases Section,
an Transplantation (DETO),
e 11, 70124 Bari, Italy.
hotmail.it (F. Cortese).
015.09.007
Pediatric Association. Published
commons.org/licenses/by-nc-ndinfants, with an incidence ranging from 1e5/1000 live
births to 49e170/1000 live births.1
It is defined by the presence of infections involving
bloodstream, urine, cerebrospinal/peritoneal structures,
and/or any other sterile tissues. Bacteria and viruses are
the most frequent causative agents; at the same time,
fungi and parasites play a minor but important role in
neonatal sepsis etiology.2
According to the time and mode of infection, we can
distinguish the following types: early onset sepsis (EOS),
caused by maternal intrapartum transmission of invasiveby Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
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cultures during the first 7 days of life or during the first 72
hours of life in the case of VLBW infants3 and late-onset
sepsis (LOS) when infection is demonstrated in blood and
cerebrospinal fluid cultures after 7 days from delivery,
caused by a postnatal acquisition (nosocomial or commu-
nity sources) of the pathogen.4 This is a common compli-
cation of the prolonged hospitalization of preterm
newborns into the Neonatal Intensive Care Units (NICUs).
The aim of this review is to evaluate the literature data
about neonatal sepsis. We separately considered EOS and
LOS. Each category has been evaluated for its incidence,
causative risk factors, clinical manifestations, as well as
methods of diagnosis and treatment, in order to give a
comprehensive overview about this worrisome clinical
problem.
2. Pathogenesis
2.1. EOS
EOS is due to infections occurring during the intrapartum
period or just before delivery, in agreement with a sort of
“vertical transmission”.
The incidence isw1e2 per 1000 live newborns, reaching
a mortality rate of w3% among term newborns, and w16%
in VLBW infants.5e7
Babies can become ill before or during labor due to an
ascending infection caused by bacteria colonization of the
maternal perineum or due to the direct contact between
these microorganisms and the body of the newborn during
the delivery. Maternal hematogenous transmission and
chorioamnionitis can further be considered as possible
conditions able to induce EOS. Aspiration and digestion of
infected amniotic fluid in utero or infected secretion in the
birth canal can effectively produce pneumonia and/or
sepsis.6
The most common source of pathogens is maternal
vaginal bacterial flora; therefore, maternal antibiotic
therapy could prevent newborns infection.8 Nevertheless,
the prophylactic administration of antibiotics is only
allowed in case of a real probability of infection because of
the potential risk for infants coming from maternal drugs
administration.9
2.2. LOS
LOS is due to microorganisms acquired from the environ-
ment after the delivery (nosocomial community-acquired
infections); preterm infants, especially if VLBW, are most
involved. The recent advances in their management have
resulted in a significant increase in survival, associated at
the same time with prolonged hospitalization, mechanical
ventilation, use of invasive procedures and devices (i.e.,
intravascular catheters and endotracheal tubes), which are
all predisposing factors to LOS. Moreover, VLBW immaturity
of the immune system makes them particularly susceptible.
In the Neonatal Research Network (NRN) cohort, 70% of
infections were associated with Gram-positive organisms;
coagulase-negative staphylococci (CoNS) contributed 48%,
Gram-negative 18% and fungal 12%.10 In late pretermnewborns (gestational age, 34e37 weeks) the incidence is
about 6e10%.11 Mortality rates increase with postnatal age,
reaching 36% in newborns aged 8e14 days and 52% in those
aged 15e28 days.10
3. Risk factors
3.1. EOS
We can distinguish maternal and neonatal factors.
3.1.1. Maternal factors
Premature birth (< 37 weeks), premature and prolonged
time (> 18 hours) of membranes rupture, maternal peri-
partum infection, and low socioeconomic status are
strongly associated with EOS.
Chan et al6 further differentiated the categories of
predisposing factors into the following: maternal infection,
maternal colonization, and risk factors for infection. They
defined maternal infection according to the following
criteria: the presence of laboratory confirmed bacterial
infection [bacteremia, amnionitis, urinary tract infections,
or chorioamnionitis; documented by positive cultures of
biologic fluids; positive polymerase chain reaction (PCR) at
the level of the amniotic fluid only; or histopathologically
confirmed chorioamnionitis] or clinical signs of infection
[intrapartum maternal fever, uterine tenderness, maternal
tachycardia, malodorous vaginal discharge, elevated white
cell count, elevated C-reactive protein (CRP), physician
diagnosis of clinical chorioamnionitis]. Maternal coloniza-
tion was determined if positive reproductive tract/genital
bacterial cultures with or without signs or symptoms of
infection were identified; and maternal risk factors
included prelabor rupture of membranes (rupture of
membranes before the onset of labour at  37 weeks of
gestation), preterm prelabor rupture of membranes
(rupture of membranes prior to onset of labour at < 37
weeks of gestation) and prolonged rupture of membranes
(duration of rupture of membranes > 8e24 hours or
undefined).6
The multivariate logistic regression analysis of a Chinese
1:4 caseecontrol study5 involving 147 EOS newborns and
588 controls showed that maternal age > 35 years [odd
ratio (OR) Z 4.835, 95% confidence interval
(CI) Z 1.170e19.981], cesarean section (OR Z 0.103, 95%
CI Z 0.041e0.258), and premature rupture of membranes
(OR Z 0.207, 95% CI Z 0.078e0.547) represent the major
predisposing factors to neonatal sepsis. Furthermore, in the
univariate analysis, fixed occupation of mothers
(OR Z 0.439, 95% CI Z 0.289e0.668), urban residence
(OR Z 5.079, 95% CI Z 2.899e8.990), abnormal fetal po-
sition (ORZ 1.621, OR 95% CIZ 1.340e1.962), fetal times
(OR Z 1.212, OR 95% CI Z 1.041e1.412), parity
(OR Z 1.859, OR 95% CI Z 1.188e2.908), amniotic fluid
volume abnormalities (OR Z 0.200, OR 95%
CI Z 0.054e0.745), pregnancy-induced hypertension
(OR Z 0.297, OR 95% CI Z 0.122e0.726), and placental
abnormalities (OR Z 0.050, OR 95% CI Z 0.006e0.428)
seemed to predispose to neonatal infection, but these re-
sults were not confirmed by multivariate regression analysis
evaluation.5
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questioned although it was previously considered as an
important predisposing factor to neonatal sepsis probably
in relation to the higher rate of group B streptococcus (GBS)
colonization into the maternal vagina.3 Epidemiological
studies showed an increased incidence of EOS in black
newborns as compared to white ones, although the expla-
nation seemed to be better related to the different socio-
economic conditions between the two ethnicities.12
Certain obstetric practices such as invasive fetal moni-
toring, membrane-stripping, and intrapartum vaginal
exams may all promote early infections.13
3.1.2. Neonatal factors
Among neonatal factors able to promote EOS, the alter-
ations of the innate immune response can play a significant
role. As the adaptive response requires 5e7 days from de-
livery to develop, during this period infants are largely
dependent on innate immune system (respiratory and in-
testinal) barriers and the skin, local immune sentinel cells,
[macrophages, endothelium, epithelium, poly-
morphonuclear cells (PMN), and dendritic cells], antigen-
presenting immune cells (monocytes, macrophages, and
dendritic cells), host defense proteins and peptides (com-
plements, cytokines, chemokines, active phase, and coag-
ulation proteins), as well as passively acquired
immunoglobulin from the mother. Defects of immunoregu-
latory genes (mainly X-linked) and prematurity (especially
with LBW) are associated with an incomplete maturation
and/or function of the innate immune system resulting in
an increased likelihood of infections.14
Birth weight also determines a major susceptibility to
EOS; preterm neonates, especially VLBW, showed inci-
dence rates > 10 times higher than those born at term
with a total mortality of about one-third.15 Furthermore,
prematurity (OR Z 0.059, 95% CI Z 0.010e0.329) and
newborn jaundice (OR Z 0.092, 95% CI Z 0.021e0.404)
seemed to predispose to EOS in a multivariate analysis of a
recent case-control study.5 Other neonatal risk factors
include male sex, neonatal Apgar scoring at 1 minute and
at 5 minutes, wet lung, fetal distress, anemia, intraven-
tricular hemorrhage, hypothermia, and metabolic
disorders.2,6
3.2. LOS
A review of studies from the NICHD Neonatal Research
Network including VLBW registry data on infection showed
that the likelihood of developing LOS was inversely related
to gestational age and birth weight [highest in infants < 25
weeks gestation (46%) and 401e750 g (43%)].10 Moreover,
while maternal intake of corticosteroids was associated
with a significant reduction in EOS (unadjusted OR 0.52; 95%
CI, 0.31e0.88), it was also associated with an increased risk
of LOS (unadjusted OR 1.29; 95% CI, 1.10e1.51) and of
sepsis at any time in the hospitalization (unadjusted OR
1.22; 95% CI, 1.09e1.37). Nevertheless, the increased
incidence of LOS in newborns having undergone antenatal
administration of corticosteroids must be balanced with the
significant reduction in death rates, intraventricular hem-
orrhage, respiratory distress syndrome, bronchopulmonarydysplasia, and risk of EOS observed after corticosteroids
use.10
A Swedish retrospective caseecontrol study demon-
strated that the risk of LOS was directly related to duration
of central/umbilical catheters and ventilatory treatment
(OR 2.6 and OR 1.6, respectively). Premature rupture of
membranes, fever during delivery, and days of continuous
positive airway pressure treatment did not seem to pre-
dispose to LOS (p Z not significant).16 A retrospective,
matched, caseecontrol study performed on 164 Taiwanese
case infants with bloodstream infections and as many
controls showed that parenteral nutrition (OR 6.07; 95% CI,
1.14e32.32; p Z 0.034) and intraventricular hemorrhage
(OR, 2.68; 95% CI, 1.20e5.99; p Z 0.017) were indepen-
dently associated with bloodstream infections after multi-
variate analysis.17
Moreover, a retrospective United States (US) cohort
study, evaluating NICUs patients with peripherally inserted
central catheters from 2003 to 2010, showed that catheter
removal due to adverse events is significantly associated
with LOS and that antibiotic use before removal is not
associated with a decline in sepsis rate.18
4. Microorganisms associated with EOS
EOS can be determined by bacteria, fungi, viruses, or pro-
tozoa; bacteria are the most frequent. Streptococcus aga-
lactiae and Escherichia coli are the agents most commonly
involved, followed by Listeria monocytogenes, Strepto-
coccus pyogenes, Viridans streptococci, Streptococcus
pneumoniae, Haemophilus influenza, Staphylococcus (S.)
aureus, Enterococci, and Pseudomonas aeruginosa.6,19
4.1. GBS
Streptococcus agalactiae (Lancefield GBS) still represents
the pathogen mainly responsible for neonatal sepsis (70% of
GBS diseases) and meningitis despite the use of intrapartum
antibiotic prophylaxis (IAP). Data from low and high income
countries showed a total GBS EOS incidence of about 0.43%
(95% CI 0.37e0.49), with the highest values in African pa-
tients (0.53%, 95% CI 0.15e0.92), followed by the Ameri-
cans (0.50%, 95% CI 0.43e0.57), and Europeans (0.45%, 95%
CI 0.34e0.56). Southeast Asia shows the lowest rates of
incidence (0.11%, 95% CI 0.012e0.220).20 The average
mortality rate was 9.6% (95% CI 7.5e11.8), showing EOS
from GBS (12.1%, 95% CI 6.2e18.3), a mortality rate twice
that of LOS (6.8%, 95% CI 4.3e9.4).21 The mortality rate was
three times higher in low-income countries (12.6%, 95% CI
10.8e14.9) than in high-income ones (4.6%, 95% CI
2.1e9.1).22
The GBS serotype III is often associated with meningitis
while types Ia, II, III, and V are associated with EOS.20
Gastrointestinal and genitourinary maternal GBS coloniza-
tion may be the sources for newborn contamination.
Infection may occur within the first 7 days of life, although
it can appear even within the first 12 hours from delivery in
the form of sepsis and pneumonia.21 Gestational age is
tightly related to death in GBS EOS; a mortality rate of
20e30% among infants with gestational age < 33 weeks was
detected, and this was 2e3% in full-term newborns.22
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infections recommended universal screening for GBS colo-
nization in pregnant women at 35e37 weeks of gestation
and prophylactic administration of penicillin as the first-
line antibiotic agent.9,23
The available data suggest that IAP is effective in pre-
venting neonatal GBS infections.24,25
Recent estimates showed that chemoprophylaxis signif-
icantly reduced the incidence of early GBS infection
compared to no treatment in developed countries (Relative
Risk (RR), 0.17; 95% CI 0.04e0.74).24
Moreover, data from the US highlighted that IAP was
associated with a reduction of invasive early-onset GBS
disease by more than 80%, from 1.8 cases/1000 live births in
the early 1990s to 0.26 cases/1000 live births in 2010, with
over 70,000 prevented cases of early-onset GBS invasive
diseases from 1994 to 2010.25
Vaccination of pregnant women is an alternative strat-
egy for preventing neonatal sepsis. A trivalent GBS
polysaccharide-protein conjugate vaccine (capsular epi-
topes from serotypes Ia, Ib and III) has completed Phase II
trials.26 An analytic model estimated that vaccination
against GBS would prevent 4% of US preterm births and
60e70% of neonatal GBS infections.27
Moreover, a recent US cost-effectiveness study high-
lighted that the addition of routine GBS maternal vaccina-
tion to screening and IAP would prevent an additional 899
cases of GBS disease and an additional 35 deaths among
infants, with estimated annual cost savings of $43.5
million.28
In particular, GBS vaccine could be a valuable tool in
low- and middle-income countries, where chemoprophy-
laxis is often not feasible.
According to a recent a decision-analytic model in South
Africa, GBS vaccination alone would prevent 30e54% of
infant GBS cases as compared to doing nothing. IAP alone,
compared to doing nothing would prevent 10% of infant GBS
cases, and vaccine plus IAP 48% of cases.26
4.2. Escherichia coli
E. coli is a Gram-negative bacterium that commonly colo-
nizes human urogenital and enteric tracts. It is considered
the second most common pathogen related to EOS onset in
term infants and the major determinant of neonatal sepsis
in VLBW newborns.12 Its antigenic structure has several
virulence factors [adhesion molecules (F1, P, and S
fimbriae), iron-sequestering systems, hemolysin, capsules
(K1, K5), lipopolysaccharide O-antigen and others with
unclear function (Tsh, IbeA, CNF1, CDT, TraT)], whose
combination determines its pathogenic power. In partic-
ular, K1 and O18 strains are associated with a higher rate of
neonatal meningitis and septicemia, as well as higher
mortality rates.29 The great resistance degree to ampicillin
(85% of cases) increases its virulence.30
4.3. Other causal agents
GBS and E. coli are the most common agents inducing EOS,
together accounting for about 70% of cases.3,31 Neverthe-
less, other microorganisms should be considered. L.monocytogenes is a facultative anaerobic Gram-positive
bacterium which can colonize the intestine. It is associ-
ated with invasive disease, spontaneous abortions, or
stillbirth.6 Streptococcus pyogenes and viridians, Strepto-
coccus pneumoniae, H. influenzae, S. aureus, Enterococci,
and P. aeruginosa are uncommon sources for EOS, but
several reports documented neonatal infections deter-
mined by these agents.32,335. Microorganisms associated with LOS
According to NICHD Neonatal Research Network data, about
70% of the first episodes of LOS are caused by Gram-positive
bacteria; CoNS were the most common pathogens (68% of
Gram-positive infections and 48% of all infections), fol-
lowed by S. aureus (8%), Enterococcus species (3%), and
GBS (2%). Gram-negative organisms were responsible for
18% of LOS. The remaining 12% were caused by fungal or-
ganism, of which Candida albicans was the most repre-
sented (6%).10
The average incidence of LOS (7e89 d) is 0.24% (95% CI
0.17e0.30); the highest values were reached in Africa
(0.71%, 95% CI 0.38e1.04), followed by the Americas
(0.31%, 95% CI 0.16e0.89).18
5.1. CoNS
CoNS are a type of Staphylococci which are unable to pro-
duce coagulase. In nosocomial infections S. epidermidis is
the most commonly found pathogen; S. aureus is isolated in
8% of cases, while S. capitis, S. haemolyticus, and S.
hominis are rarely involved.34 S. epidermidis commonly
colonizes human skin and mucosal membranes and rarely
causes infections in healthy tissues but is capable of
adhering and proliferating on plastic surfaces of indwelling
medical devices, thanks to its ability to form persistent
multilayered agglomerations called biofilms, which are
intrinsically resistant to antibiotics and a real barrier
against the attacks of the immune system.5,35 Immuno-
compromised patients and premature neonates are the
most vulnerable individuals to be exposed to CoNS
infections.36
Furthermore, resistance to antibiotics appears to be
widespread for S. epidermidis, to methicillin in particular
(methicillin-resistant S. epidermidis, MRSE). This type of
resistance (90% of isolated S. epidermidis) is encoded by
the mecA gene, located on mobile genetic elements, and
therefore it is transferable to different bacterial strains.
Vancomycin is used in MRSE cases.5,35
5.2. Other organisms
Gram-negative bacteria (i.e., E. coli, Klebsiella, Pseudo-
monas, Enterobacter, and Serratia) are responsible for
approximately a quarter of LOS cases, while fungi (C.
albicans the most common) account for about 12%. The
related mortality rates are high.11 Gram-negative in-
fections usually occur by transmission from health care
personnel, contamination of bladder and venous catheters,
parenteral solutions and pediatric formulas.37
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birth weight, male sex, forms other than enteral nutrition,
and antibiotic treatment with cefalosporins represent the
main risk factors for neonatal infection.
6. Clinical manifestations
EOS and LOS present common and unspecific clinical man-
ifestations. Medical diagnosis is particularly difficult in
preterm and LBW infants due to the immaturity of the im-
mune system that makes signs and symptoms misleading.
The degree of clinical manifestations is highly variable
depending on the virulence of pathogens and on the
mechanisms of host defense. Body temperature may be
elevated, normal, or depressed; low temperatures with
irregular fluctuations are often present in preterm new-
borns.39 Motor functions are characteristically reduced;
delayed weight gain, pale skin, and reduction of activity
(movements, eating, crying) are often observed. Cyanosis,
apnea, tachycardia, bradycardia, and hypotension repre-
sent warning signs for severe and rapidly evolving forms as
they can be considered precursors of shock (cold extrem-
ities, decreased femoral pulses, congestive heart failure,
and even disseminated intravascular coagulation). Jaundice
may sometimes be the only manifestation, preceding en-
cephalopathy in severe cases. All organs and systems may
be affected; the central nervous system involvement can
induce drowsiness, irritability, lethargy, convulsions, and
increased tension at the fontanelle’s level. Anorexia,
regurgitation, abdominal distension, vomiting, diarrhea,
and necrotizing enterocolitis are common symptoms of
gastrointestinal lesions. Skin lesions are frequent; these
include cutaneous and mucosal petechiae, impetigo,
cellulitis and abscesses. Involvement of cardiovascular
system (myocarditis, pericarditis, endocarditis, heart fail-
ure), septic shock with thrombotic-hemorrhagic manifes-
tations, urinary tract infections, osteomyelitis, and deep
infections are also possible.
7. Diagnosis
Serum inflammatory biomarkers (acute-phase reactants,
inflammatory cytokines) may be helpful, although no lab-
oratory test alone is sufficient for the absolute diagnosis.
For this reason, delays may occur in the identification of
affected infants. This delay in identifying affected infants
may lead to prolonged and unnecessary therapy, the
emergence of resistant microorganisms, the growth of
health care spending, and especially a higher risk of com-
plications such as cerebral palsy or intraventricular
hemorrhage.
In order to make a diagnosis, several clinical and he-
matological parameters are generally considered together,
although the correct combination is not well-established.
Rodwell et al40 formulated a hematologic scoring system
(HSS), which was easy to perform and cost-effective, based
on the following seven criteria: high values of total leuko-
cytes count; high PMN level count; elevated immature PMN
count; elevated immature-to-total-PMN ratio; immature-
to-mature PMN ratio  0.3; platelet count  150,000/
mm3; and pronounced degenerative changes in PMNs. Ascore > 2 means likelihood of sepsis, whereas  2 is related
to 99% likelihood of sepsis absence.40 Moreover, some new
leukocyte parameters (neutrophil and monocyte volume,
conductivity, scattering, and volume distribution width)
may be useful in the differential diagnosis of newborn
sepsis.41
Macrophage cytokines, which are produced in response
to microorganism antigens and which stimulate the release
of acute-phase reactants and hence the host inflammatory
immune reaction, are usually used in clinical practice as
indicators of both EOS and LOS.42 Moreover, serum markers,
increasing earlier than changes in hematological parame-
ters, play a pivotal role in the diagnostic process, allowing
detection of sepsis and its severity, differentiation of bac-
terial from fungal and viral agents, and monitoring of
response to therapy.43 The proinflammatory cytokine tumor
necrosis factor-alpha (TNF-a) measured in cord blood
seems to be increased in neonates with EOS (sensitivity,
78.0%; specificity, 41.2%).44 Interleukin-6 (IL-6) and IL-8
plasma concentrations are considered to be sensitive and
specific for the prediction of neonatal sepsis. These in-
dicators can be detected in blood early but their short half-
life, of about 12e24 hours, limits their use in clinical
practice.45
CRP, a peptide synthesized by the liver in response to
infection or inflammatory processes, was shown to be the
best diagnostic marker of neonatal sepsis, with higher
sensitivity and specificity than total PMN count and
immature-to-total-PMN ratio.46 However, it presents a low
sensitivity during the early phases of infection due to the
time needed for release (about 6 hours). Serial de-
terminations improve the diagnostic accuracy and are
useful for evaluating the response to treatment.47
The granulocyte colony-stimulating factor was shown to
have sensitivity of 95% and negative predicting value (NPV)
of 99% in detecting infection in neonates of all gestational
ages when a cut-off level of 200 pg/mL was used.48
Moreover presepsin, a truncated form of soluble CD14,
can be used as a reliable biomarker for LOS and treatment
response in preterm infants.49
Procalcitonin (PCT), a peptide produced by monocytes
and hepatocytes in response to systemic inflammation,
seems to be more specific than CRP in bacterial in-
fections.50 In neonatal sepsis, its concentrations increase
after 4 hours from proinflammatory action of bacterial
endotoxins, reaching the peak after 6e8 hours, so a rise
of PCT value is more precocious compared to CRP. In
normal-birth-weight neonates, a PCT cut-off limit >
0.5 ng/mL indicates a two-fold probability of nosocomial
sepsis, while a value > 2.4 ng/mL in infected VLBW in-
fants suggests the need for an empirical antibiotic
therapy.51
Leukocyte differentiation antigens, CD33, CD66b, and
CD19, induced by inflammation secondary to bacterial in-
fections, increase in preterm newborns with sepsis. In
addition, an increased expression of PMN Fc-gamma-
receptor I (CD64) has been demonstrated in newborns
during the early phase of an acute bacterial infection.52
Weirich et al53 proposed neutrophil CD11b as a preco-
cious marker of neonatal infection. In their study, NPV,
positive predicting value (PPV), sensitivity, and specificity
were 100%, 99%, 96%, and 100%, respectively.53
Table 1 Neonatal sepsis: summary table.
Types of neonatal
sepsis
Early onset sepsis Late onset sepsis
Definition Neonatal infection during the 1st 7 d of life or
during the 1st 72 h of life in case of VLBW infants.
Neonatal infection after 7 d from delivery.
Epidemiology Incidence of 1e2 per 1000 live newborns. Prevalence of w25e30% in VLBW infants,
incidence of w6e10% in late preterm newborns
(gestational age, 34e37 wk)
Mortality 3% among term newborns, & w16% in VLBW
infants
36% in VLBW babies aged between 8 d & 14 d & 52%
in those aged between 15 d & 28 d
Physiopathology Vertical transmission from mother: infection
contracted from bacteria colonizing the maternal
perineum, maternal hematogenous transmission
or chorioamnionitis.
Infection is acquired after the delivery; preterm &
VLBW infants are most frequently involved.
Predisposing
factors
Maternal factors: premature birth (< 37 wk),
premature or prolonged time (> 18 h) of
membranes rupture, maternal peripartum
infection, a low socioeconomic status, maternal
age < 20 y & > 35 y, cesarean section, black
ethnicity, obstetric practices, having previously
had an infant with GBS infection.
Neonatal factors: alterations of the innate
immune response, defects of immunoregulatory
genes, prematurity, birth weight, newborn
jaundice, male sex, neonatal Apgar scoring, wet
lung, fetal distress, anemia, intraventricular
hemorrhage, hypothermia, & metabolic disorders.
The risk is inversely related to gestational age &
birth weight, other risk factors are maternal
intake of corticosteroids, antenatal administration
of corticosteroids in babies, prolonged
hospitalization, mechanical ventilation, invasive
procedures, & devices implantation.
Causative
microorganisms
Streptococcus agalactiae & Escherichia coli are
the agents most commonly found, but all
microorganisms may be responsible.
About 70% of the 1st episodes of LOS are caused by
Gram-positive bacteria; CoNS are the most
common pathogens. Gram-negative organisms are
responsible for 18% of cases. The remaining 12%
are caused by fungal organisms.
Clinical
manifestations
Clinical manifestations are common & unspecific: fever, cyanosis, apnea, tachycardia, bradycardia,
hypotension, jaundice, drowsiness, irritability, lethargy, convulsions, anorexia, regurgitation, abdominal
distension, vomiting, diarrhea, skin lesions, involvement of cardiovascular system, septic shock, urinary
tract infections, osteomyelitis, & deep infections.
Diagnosis  Serum inflammatory biomarkers (acute-phase reactants, inflammatory cytokines, alterations in blood
tests);
 Identification of causative agent through molecular genetics techniques (amplification of target DNA/
RNA fragments);
 Microbiological exams on biological samples (blood, urine, cerebrospinal fluid).
Prevention Universal GBS screening of all pregnant women at
35e37 wk of gestation & in case of positive test,
intrapartum antibiotic prophylaxis at least 4 h
before the delivery.
Reduce, as far as possible, the sources of
contamination (ensuring a sterile environment in
NICUs, minimizing the invasive procedures)
Therapy  Empiric therapy as 1st line: ampicillin & an
aminoglycoside are recommended
 Then, target antibiotic therapy on the base of
culture exams.
 Empiric therapy as 1st line: vancomycin & an
aminoglycoside are recommended
 Then, target antibiotic therapy on the base of
results of culture exams.
CoNS Z coagulase-negative Staphylococci; GBS Z group B-streptococcus; LOS Z late-onset sepsis; NICUs Z neonatal intensive care
units; VLBW Z very low birth weight.
270 F. Cortese et alIn preterm neonates with EOS, a prenatal immune
response with increased umbilical plasma levels of cyto-
kines (TNF-a, CRP, IL-1b, IL-6, IL-8, p55, p75, and IL-1 re-
ceptor antagonist) has been demonstrated.54 IL-1b, IL-6,
and IL-8 were the most specific55 in this clinical setting.
Recent proteomics-based technologies provided novelbiomarkers for identifying pregnancies at risk for intra-
uterine infection and prenatal fetal damage.55
Molecular genetics techniques can further help physi-
cians in the diagnosis of neonatal sepsis by identifying
specific fungal, bacterial and viral genes in neonatal blood
through amplification of target DNA/RNA fragments. The
Clinical signs &
symptoms 
suggestive of 
neonatal sepsis
Consider ways of onset 
(immediately after birth, after 7 
d from delivery), the presence 
of risk factors (prematurity, low 
birth weight, hospitalization, 
maternal infection, etc.)
Perform 
microbiological &
blood tests
Diagnose early-
onset sepsis or 
late-onset sepsis
Empirical 
antibiotic therapy
as 1st line &
therefore specific 
antibiotic therapy
Figure 1 The management of neonatal sepsis step by step.
Sepsis in newborns 271amplification of 16S rRNA gene with PCR had 100.0% sensi-
tivity, 95.4% specificity, 77.2% PPV, and 100.0% NPV as
compared to blood culture.56
A recent comparative study highlighted that the 16S
rDNA PCR assay was more sensitive than blood culture in
diagnosis of EOS; the combination of high sensitivity-CRP,
PCT, and IL-6 was better than single markers, and among
them PCT had the greater diagnostic value.57 As regards
instrumental evaluation, echocardiography and ultrasound
assessments of peripheral vessels58 are not really of help to
physicians in early detection of EOS or LOS onset. The
involvement of the cardiovascular system represents, in
fact, a late and often irreversible manifestation of
advanced stages of the septic state, and the ultrasound
evaluation can only confirm this condition.
To the best of our knowledge, the definitive diagnosis is
still microbiological as cultural exams on biological samples
(blood, urine, cerebrospinal fluid) are considered the gold
standard for the detection of bacteremia or fungemia,
despite their limitations of low sensitivity (sepsis due to
bacterial endotoxins induce negative cultures) and the time
required for results (48e72 h), which can retard the
beginning of antibiotic therapy and compromise the life of
newborns.598. Prevention and treatment
The primary objective to be achieved is the correct pre-
vention of neonatal sepsis. Recent guidelines recom-
mended the universal GBS screening of all pregnant women
at 35e37 weeks of gestation.9,23 Furthermore, they speci-
fied the IAP by using penicillin, ampicillin, cefazolin, or
clindamicin (in case of documented, anamnestic penicillin
allergy) at least 4 hours before the delivery.23
Other prophylactic strategies included breastfeeding,
prevention of health care-associated infections, adminis-
tration of lactoferrin, antistaphylococcal monoclonal anti-
bodies, immunoglobulin, granulocyte-macrophage colony-
stimulating factors, probiotics, and fluconazole (in case of
Candida infections).60
In the presence of symptoms and signs suggestive of
neonatal sepsis, empiric therapy should be undertaken
pending the identification of the causative agent: ampicillin
and an aminoglycoside are recommended as empiric ther-
apy for EOS; vancomycin and an aminoglycoside for LOS;
and cephalosporin if Gram-negative meningitis is sus-
pected. The specific therapy for the causative pathogen
should be adopted as soon as possible based on cell culture
results. The duration of treatment varies from 7 days to 21
days, depending on the type of pathogen and the site of
infection (meningitis, cerebritis, osteomyelitis, andendocarditis). The pharmacological treatment is stopped
when no pathogen is identified and no signs and symptoms
of infection can be observed.60
The summary table (Table 1) and the flow chart
(Figure 1) respectively summarize the main features and
the clinical approach to neonatal sepsis.9. Conclusion
Neonatal sepsis continues to be an important cause of
morbidity and mortality worldwide due to the lack of
adequate preventive and therapeutic strategies in low in-
come settings and due to the increased survival of preterm
and low-weight newborns with lengthy stays in NICUs in
high-income countries. Much remains to be done in order to
minimize the neonatal mortality rates.Conflicts of interest
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